Open AccessFunctional and Transcriptional Characterization of Histone Deacetylase Inhibitor‐Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell‐Derived Cardiomyocytes
Author(s) -
Kopljar Ivan,
Gallacher David J.,
De Bondt An,
Cougnaud Laure,
Vlaminckx Eddy,
Van den Wyngaert Ilse,
Lu Hua Rong
Publication year - 2016
Publication title -
stem cells translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.781
H-Index - 71
eISSN - 2157-6580
pISSN - 2157-6564
DOI - 10.5966/sctm.2015-0279
Subject(s) - cardiotoxicity , histone deacetylase , vorinostat , histone deacetylase inhibitor , induced pluripotent stem cell , epigenetics , medicine , panobinostat , pharmacology , adverse effect , cancer research , histone , bioinformatics , biology , embryonic stem cell , chemotherapy , biochemistry , gene
Patients treated with histone deacetylase (HDAC) inhibitors, which are used for some cancers, neurological diseases, and immune disorders, can experience various cardiac adverse events. This study found that human induced pluripotent stem cell‐derived cardiomyocytes can predict cardiac adverse events in patients caused by HDAC inhibitors.